Panbela Therapeutics Inc
NASDAQ:PBLA
Panbela Therapeutics Inc
Research & Development
Panbela Therapeutics Inc
Research & Development Peer Comparison
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Panbela Therapeutics Inc
NASDAQ:PBLA
|
Research & Development
-$20.6m
|
CAGR 3-Years
-102%
|
CAGR 5-Years
-63%
|
CAGR 10-Years
-54%
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$7.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-9%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-10%
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.5B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-14%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$4.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-17%
|
See Also
What is Panbela Therapeutics Inc's Research & Development?
Research & Development
-20.6m
USD
Based on the financial report for Dec 31, 2023, Panbela Therapeutics Inc's Research & Development amounts to -20.6m USD.
What is Panbela Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-54%
Over the last year, the Research & Development growth was 27%. The average annual Research & Development growth rates for Panbela Therapeutics Inc have been -102% over the past three years , -63% over the past five years , and -54% over the past ten years .